PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Centanafadine SR 400 mg Shows 52-Week Tolerability in Adult ADHD

centanafadinetriple reuptake inhibitorADHDadult ADHDopen-label extensionlong-term safetypsychopharmacologyphase 3 Psychiatry / Psychopharmacology

Background Information

Centanafadine shows promise as a long-term ADHD treatment.

Long-term safety and efficacy of centanafadine, a triple reuptake inhibitor, are evaluated for treating adult ADHD. Centanafadine was generally well-tolerated with 61.4% experiencing treatment-emergent adverse events. Mean reduction in ADHD symptoms was significant at 52 weeks. As an open-label, phase 3 trial, these exploratory results suggest centanafadine may be a viable long-term treatment for adults with ADHD, pending further studies. Centanafadine shows promise for long-term management of adult ADHD with favorable safety and efficacy.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Turkoglu O, Skubiak T, McDonough J

Citation: Turkoglu O, Skubiak T, McDonough J 52-Week Open-Label Safety and Tolerability Trial of Centanafadine Sustained Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD). CNS spectrums. 2024;29(5):507. doi:10.1017/S1092852924001755

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.